BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37670372)

  • 1. Severe hypercalcemia due to metastatic pancreatic neuroendocrine tumor: a case report.
    Behdadnia A; Jeddi M
    J Med Case Rep; 2023 Sep; 17(1):400. PubMed ID: 37670372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case Report: Unmasking Hypercalcemia in Patients With Neuroendocrine Neoplasms. Experience From Six Italian Referral Centers.
    Giannetta E; Sesti F; Modica R; Grossrubatscher EM; Guarnotta V; Ragni A; Zanata I; Colao A; Faggiano A
    Front Endocrinol (Lausanne); 2021; 12():665698. PubMed ID: 34093441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignant hypercalcaemia related to parathyroid hormone-related peptide (PTHrP) secretion from a metastatic pancreatic neuroendocrine tumour (NET).
    Symington M; Davies L; Kaltsas G; Weickert MO
    BMJ Case Rep; 2017 Mar; 2017():. PubMed ID: 28331027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral hypercalcemia of malignancy caused by parathyroid hormone-related peptide-secreting neuroendocrine tumors. Report of six cases.
    Milanesi A; Yu R; Wolin EM
    Pancreatology; 2013; 13(3):324-6. PubMed ID: 23719609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unusual complication of a pancreatic neuroendocrine tumor presenting with malignant hypercalcemia.
    Kanakis G; Kaltsas G; Granberg D; Grimelius L; Papaioannou D; Tsolakis AV; Öberg K
    J Clin Endocrinol Metab; 2012 Apr; 97(4):E627-31. PubMed ID: 22319031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin receptor expression in a parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumour causing severe hypercalcaemia.
    Müssig K; Petersenn S; Wehrmann M; Horger M; Vierling P; Häring HU; Gallwitz B
    Eur J Gastroenterol Hepatol; 2007 Aug; 19(8):719-23. PubMed ID: 17625444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of Severe and Refractory Humoral Hypercalcemia With 177Lu-Octreotate Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumor of the Pancreas.
    Iliuta IA; Beauregard JM; Couture F; Douville P; Mac-Way F
    Clin Nucl Med; 2015 Sep; 40(9):e448-50. PubMed ID: 26053724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatic Neuroendocrine Tumor With Humoral Hypercalcemia and High Tumor PD-L1 Score.
    Copur MS; Vargas L; Wedel W; Merani S; Cushman-Vokoun A; Drincic A
    Oncology (Williston Park); 2020 Dec; 34(12):548-552. PubMed ID: 33395496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTHrP, calcitonin and calcitriol in a case of severe, protracted and refractory hypercalcemia due to a pancreatic neuroendocrine tumor.
    Van den Eynden GG; Neyret A; Fumey G; Rizk-Rabin M; Vermeulen PB; Bouizar Z; Body JJ; Dirix LY
    Bone; 2007 Apr; 40(4):1166-71. PubMed ID: 17188588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protracted hypocalcaemia following a single dose of denosumab in humoral hypercalcaemia of malignancy due to PTHrP-secreting neuroendocrine tumour.
    Teng J; Abell S; Hicks RJ; Hofman MS; Sachithanandan N; McKelvie P; MacIsaac RJ
    Clin Endocrinol (Oxf); 2014 Dec; 81(6):940-2. PubMed ID: 24890549
    [No Abstract]   [Full Text] [Related]  

  • 11. Hypercalcemia of malignancy caused by parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumors (PTHrP-PNETs): Case Report.
    Pitts S; Mahipal A; Bajor D; Mohamed A
    Front Oncol; 2023; 13():1197288. PubMed ID: 37377908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Case of a Rare Parathyroid Hormone (PTH)-Producing Neuroendocrine Tumor.
    Quinn CD; Chaudhary F; Gould-Simon A; Chen B; Bhandal HS; Chaudhary U
    Am J Case Rep; 2022 Jul; 23():e935783. PubMed ID: 35849548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Unusual cause of hypercalcemia in pregnancy].
    Mehl L; Schrader J; Winterberg T; Daniels T; Gross A; Weidner U; Clauditz TS; Lock G
    Z Gastroenterol; 2021 Feb; 59(2):143-148. PubMed ID: 33556973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent primary hyperparathyroidism and humoral hypercalcemia of malignancy in a patient with multiple endocrine neoplasia type 1.
    Milanesi A; Yu R; Geller SA; Burton D; Deftos LJ; Wolin EM
    Pancreas; 2011 May; 40(4):634-7. PubMed ID: 21483254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic neuroendocrine tumor associated with humoral hypercalcemia of malignancy and carcinoid tumor: a case report and review of the literature.
    Shah RH; Martinez D
    Pancreas; 2013 Apr; 42(3):549-51. PubMed ID: 23211368
    [No Abstract]   [Full Text] [Related]  

  • 16. Paraneoplastic hypercalcemia in a patient with adenosquamous cancer of the colon.
    Thompson JT; Paschold EH; Levine EA
    Am Surg; 2001 Jun; 67(6):585-8. PubMed ID: 11409809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus Related Fulminant Hepatitis in Pancreatic Neuroendocrine Tumor With Liver Metastases: A Case Report and Literature Review.
    Chang SC; Tsai CY; Liu KH; Wang SY; Hsu JT; Yeh TS; Yeh CN
    Front Endocrinol (Lausanne); 2021; 12():639967. PubMed ID: 33868173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic neuroendocrine tumor with extensive vascularisation and parathyroid hormone-related protein (PTHrP)--associated hypercalcemia of malignancy.
    Clemens P; Gregor M; Lamberts R
    Exp Clin Endocrinol Diabetes; 2001; 109(7):378-85. PubMed ID: 11573150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant islet cell tumor associated with hypercalcemia.
    Mao C; Carter P; Schaefer P; Zhu L; Dominguez JM; Hanson DJ; Appert HE; Kim K; Howard JM
    Surgery; 1995 Jan; 117(1):37-40. PubMed ID: 7809834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of two patients with metastatic neuroendocrine tumours treated with octreotide.
    van de Loosdrecht AA; van Bodegraven AA; Sepers JM; Sindram JW
    Neth J Med; 1998 Sep; 53(3):118-23. PubMed ID: 9803143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.